The Next Step in DES Evolution
Medinol’s patented eDES technology* (eDES: elastomer Drug-Eluting Stent) was developed in response to ongoing clinical concerns of complications associated with traditional DES surface quality and integrity.
eDES changes the face of drug-eluting stenting by lowering the risks associated with surface imperfections and deformations that can lead to polymer cracking and peeling. The elastomer coating and coating process ensure comprehensive and controlled drug elution, eliminating the surface irregularities and deformations that have been demonstrated to be associated with inflammatory processes.
eDES Batch Coating
Brittle Polymer Concerns
From crimping through deployment and drug elution, drug-eluting stents endure substantial mechanical stress. Inherently brittle, traditional polymer coatings of drug eluting stents have been shown to develop surface imperfections and deformations, which under stress can crack and even peel away from the stent scaffolding.
This cracking and peeling can lead to uneven drug release that may result in under- and over-dosing of the vessel wall. Moreover, it could lead to inflammatory reactions, which can lower stenting safety and efficacy, and can contribute to restenosis or thrombosis.
Cracking and Peeling of Durable and Bioabsorbable Polymer in Various Drug-Eluting Stents
Elastomer Based Coating
The first stent manufacturer to offer elastomer-based coating, Medinol eliminates the risks associated with cracking and peeling, delivering a smooth elastic surface that provides uniform drug elution to the vessel wall.
The eDES surface elasticity and smoothness and its uniform drug-elution are enabled by QualitySurface™ - our proprietary manufacturing technology that enables a high quality coating of stent panels with an elastomer and drug.
eDES: Smooth and Uniform Elastomer Coating
Uniform Drug Release
eDES uniquely complements Medinol’s renowned WiZeCell stent design. With the unique combination of flexible narrow struts and wide supportive struts, the WiZeCell scaffolding minimizes variations in inter-strut gap size, even in vessel bends.
Leveraging the highly-uniform WiZeCell scaffolding, which better conforms to vessel anatomy and moves naturally with the vessel, eDES technology enables a more uniform release of drug into the vessel wall, avoiding under- and over-dosing.
* Currently in clinical studies and not approved for sale.